United States | Apotex Video
Video Transcript
Apotex believes that every man, woman, and child is entitled to affordable medical care and freedom from pain and suffering.
For over 35 years, we have met the challenges of today and tomorrow and fought hard to build a successful world wide pharmaceutical company. With an important global strategy of vertical integration, Apotex has built an impressive scientific and manufacturing infrastructure. We've done this with the objective of advancing generics.
Manufacturing, technology and science are the focus of our place in the pharmaceutical industry. The world has a tremendous need for quality, affordable medicines. Apotex wants to meet those needs for the long term. We have built the facilities, the scientific R&D base, and the technology to meet the healthcare needs of the world.
Born out of entrepreneurial efforts and strong scientific roots, Apotex today is the largest Canadian owned pharmaceutical company.
The Apotex Group of Companies has a simple yet powerful mission... "To build one of the world's most successful, independent pharmaceutical companies in R&D, quality, manufacturing, sales and customer service."
In 1974, with 2 employees and no sales, our chairman had a vision for our success and growth. Today his vision realized, Apotex leads the fight for affordable healthcare all over the globe.
We have invested in our future with a planned Research and Development program that will spend close to $2 billion within the next ten years. Presently, we produce over 300 medicines in over 4000 formats and dosages.
Our R&D program, supported by close to 2000 scientific staff including 110 PhDs out of an approximate employee count of 5000, has well over 600 products under development, from solid dosage & bio-pharmaceuticals across all technology platforms. This is accomplished through global leadership and capabilities in the development of APIs (Active Pharmaceutical Ingredients) and finished dosage formulations. We have facilities in different countries to manufacture APIs and finished dosage forms.
The Apotex Group of Companies occupies over 3.4 million square feet of facilities with state-of-the art technology to meet the needs of the world healthcare system. Research for Apotex also includes innovative medicines. Apo-Pharma was created as a separate company to handle innovative medicines. Its main accomplishment to date is the approval in 60 countries around the world of "Ferriprox" for the treatment of Thalassemia. The pipeline includes iron chelators for other indications.
Also, Cangene, a successful publicly traded biotechnology company, has the innovative product, WinRho SDF for treatment of Hemolytic Disease of the Newborn (HDN) approved, and has several other life saving immunoglobins as well. Cangene also has major research contracts with the U.S. military Bio-Defense Program.
The Apotex Group and our facilities are recognized by the world as among the best. This has resulted in approvals by the Food and Drug Administration in the U.S.; the Canadian Therapeutics Products Directorate, the European Medicines Evaluation Agency and the Australian Therapeutics Goods Administration.
These approvals have opened the doors for export to over 115 countries. Our international division continues to be a focus for growth as Apotex continues to strive to be a worldwide leader in generics.
Apotex product development also includes the new area of generic biotechnology through Cangene. Apotex is poised to be a part of this new frontier for generics.
Given our company goal to make pharmaceuticals affordable all over the world, Apotex continues to donate generously through the Apotex Foundation to global charitable causes and institutions of higher learning. We are also proud to say that we have donated medicines to every disaster and war zone around the globe.
Our true strength is our employees and our vision. From the top down we are an organization dedicated to serving the needs of our customers and our employees know that putting the needs of our customers first will help Apotex to achieve our vision of being a world leader in generic pharmaceuticals.
Now let's have a quick tour of the Apotex Group. We'll start at our headquarters area where we have eleven facilities including leading edge hi-tech manufacturing facilities and a clinical hospital. Expansions have occurred regularly over the last 8 years.
The new manufacturing facilities were built on the concept of using gravity to assist in the production process. Automated guided vehicles or AGVs do all the heavy work. Production moves from floor to floor in what is one of the most technologically advanced facilities in the world. Also, one of the key components at the head office campus are multi-million dollar laboratories in every size to house the hundreds of ongoing R&D projects currently underway at Apotex.
The BioMedical Research Group includes a clinical facility housing 104 beds. Here, the studies can be done for generic pharmaceuticals, and the early phases of new innovative medicines, a feature unique to Apotex. The head office area has specialty production facilities for the manufacture of antibiotics.
For the United States market, Apotex has built extensive facilities at our Etobicoke, Richmond Hill and Signet Campuses.
The Etobicoke Site is also a state of the art R&D and production facility using gravity to assist in the manufacturing process. Apotex continues to be among the leaders in FDA product approvals each year. With a full pipeline of new product submissions we are focused on this trend continuing. The Etobicoke campus has undergone a major expansion and was recognized as one of the five Best Pharmaceutical Manufacturing facilities in the world by the International Society of Pharmaceutical Engineers.
Liquids, ophthalmics, and nasal sprays are the key products at the Richmond Hill site of Apotex, another member of the Apotex Group. This facility uses innovative technology to manufacture its products.
Supplying fine chemicals for the production of pharmaceuticals is Apotex PharmaChem in Brantford, Ontario. A key member of the Apotex Group, it researches and develops fine chemicals to meet our objective to be vertically integrated. The facility has recently gone through a major expansion to continue to meet our growing business demands. This ability to manufacture our own active ingredient when required is a distinguishing feature for Apotex.
Also supplying fine chemicals to the Group is Apotex Fermentation in Manitoba. It has state of the art laboratories and fermentation facilities for products like cyclosporins and cholesterol reducing drugs like Pravastatin and Simvastatin.
The Apotex Group of companies includes Cangene, which focuses on the important area of biotechnology. With facilities in Canada and the U.S., Cangene is one of the most successful biotechnology companies in the world.
As you can see, we are committed to making healthcare affordable. During our 35-year history, we have built a tremendous presence in generic pharmaceuticals and we look forward to the next 30 years of growth and service to our customers.
We are proud to say, at Apotex, our innovation does not end in the lab. It just starts there... on the road to Advancing Generics.